Company Profile

Abcam plc is a global life science company. The Company serves customers at the forefront of life science research through the identification, development, and distribution of biological reagents. Its products are used by researchers around the world to study biological pathways critical for scientific research, diagnostics, and drug discovery. It offers a selection of products in its catalogue to support research on proteins in biological pathways. Its principal catalogue product lines include primary and secondary antibodies, conjugated antibodies and conjugation kits, and singleplex immunoassays. It offers a range of peptides and proteins, which include cytokines, growth factors, and enzymes. It offers a range of knockout cell lines and lysates, which are used for its in-house validation needs and are also made available to its customers for their own research. It offers a variety of other products, including cellular activity kits, biochemicals and cell signaling pathway tools.

Employees

1,760

Sector

Pharmaceuticals

More about the company

Jul. 22	Abcam Limited Appoints Kaveh Kahen as Director, Effective July 14, 2026	CI
Jun. 17	ABCAM LIMITED Announces Termination of Markus Lusser as Director, Effective June 5, 2026	CI
Apr. 28	Wall Street's Rally Looks More Fragile as Inflation Risks Build
Apr. 13	Abcam Launches SimpleStep Ignite ELISA	CI
Mar. 09	Abcam Limited Appoints Melanie Hammerschmidt-Broman as Director, Effective March 10, 2026	CI
Jan. 20	Abcam Joins the Innovative Health Initiative LIGAND-AI Project to Advance Artificial Intelligence (AI)-Driven Drug Discovery Through Open Science	CI
Jan. 11	Abcam Limited Announces Termination of Knud Mueller as Director, Effective December 31, 2025	CI
25-10-21	Molecular Instruments and Abcam Announce Broad Compatibility of the HCR HiFi Encoder with Abcam?s Rabmab and Mouse Antibody Portfolio	CI
23-12-06	Global markets live: Mastercard, Diageo, Nvidia, Airbnb, Exxon Mobil...
23-12-06	Job losses delight investors
23-12-06	Danaher Closes Acquisition of Abcam	MT
23-12-06	Danaher completes $5.7 billion acquisition of Abcam	RE
23-12-06	Abcam plc(NasdaqGS:ABCM) dropped from NASDAQ Composite Index	CI

23-10-31	RBC Trims Price Target on Abcam to $24 From $25, Keeps Sector Perform Rating	MT
23-08-30	SVB Securities Downgrades Abcam to Market Perform From Outperform, Price Target is $24	MT
23-08-28	Deutsche Bank Raises Abcam Price Target to $23.50 From $17, Maintains Hold Rating	MT
23-07-06	RBC Raises Abcam's Price Target to $25 From $22, Notes Strong Margin at H1; Keeps Sector Perform Rating	MT
23-06-20	RBC Downgrades Abcam to Sector Perform From Outperform, Trims Price Target to $22 From $23 After Recent Stock Jump, Sees 'Material Volatility'	MT

23-12-06	Danaher Completes Acquisition of Abcam	PR
23-12-04	Acquisition of Abcam by Danaher Approved by the High Court of Justice of England and Wales	BU
23-11-20	Abcam Acquisition by Danaher has received all Identified Clearances, Transaction Expected to Close on December 6, 2023	AQ
23-11-17	Abcam Acquisition by Danaher Has Received All Identified Clearances; Transaction Expected to Close on December 6, 2023	BU
23-11-06	Shareholders of Abcam Approve Proposed Acquisition by Danaher	BU

Apr. 28	Wall Streets Rally wirkt angesichts steigender Inflationsrisiken fragiler
Apr. 28	La racha de Wall Street se debilita ante el repunte de los riesgos inflacionistas
23-12-06	USA-Les valeurs à suivre à Wall Street (actualisé)
23-11-07	USA-Les valeurs à suivre à Wall Street (actualisé)
23-08-28	Aktien New York Schluss: Weitere Erholung - Anleger warten auf Daten

Manager	Title	Age	Since
Alan Hirzel CEO	Chief Executive Officer	58	2014-09-08
Markus Lusser PSD	President	58	2024-03-17
Michael Baldock DFI	Director of Finance/CFO	62	2020-02-02

Abcam plc Stock

Stocks

ABCM

US0003802040

Pharmaceuticals

Latest news : Abcam plc

Analysts' recommendations : Abcam plc

Press Releases : Abcam plc

News in other languages : Abcam plc

Quotes and Performance

Managers and Directors : Abcam plc

Latest insider transactions

Biopharmaceuticals

Company Profile

Director	Title	Age	Since
Alan Hirzel BRD	Director/Board Member	58	2013-12-31
Mara Aspinall BRD	Director/Board Member	63	2015-09-13
Giles Kerr BRD	Director/Board Member	67	2018-12-11

Date	Insider	Type	Main position	Quantity	% Market Cap.
11/28/22	Michael Baldock	Free		38,268	0.0167%
11/28/22	Michael Baldock	Sell		18,032	0.0079%
11/28/22	Alan Hirzel	Sell	Chief Executive Officer	68,853	0.0301%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ABCAM PLC	+0.04%	+0.08%	-	-	5.52B
REGENERON PHARMACEUTICALS, INC.	-1.67%	-4.78%	+37.02%	-4.42%	80.65B
CSL LIMITED	-0.90%	+0.65%	-20.11%	-34.58%	59.9B
MODERNA, INC.	-3.35%	-4.92%	+463.91%	+21.22%	57B
SAMSUNG BIOLOGICS CO.,LTD.	-6.78%	-5.59%	-5.25%	+27.67%	53.35B
UCB	-2.43%	-2.35%	+8.03%	+163.45%	49.29B
BIOGEN INC.	-1.35%	+0.79%	+64.72%	-17.56%	32.73B
INCYTE CORPORATION	-2.64%	-2.69%	+48.59%	+91.84%	25.89B
INNOVENT BIOLOGICS, INC.	-0.09%	+6.23%	+18.13%	+218.05%	23.9B
SWEDISH ORPHAN BIOVITRUM AB	-0.34%	+1.04%	+59.33%	+110.57%	17.07B
Average	-1.64%	+1.57%	+74.93%	+64.03%	44.42B
Weighted average by Cap.	-1.98%	+1.01%	+82.95%	+43.06%